Fabry Disease - Pipeline Review, H2 2017

Publisher Name :
Date: 22-Aug-2017
No. of pages: 81
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H2 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.

Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body. Symptoms include pain, diarrhea, nausea, kidney problems, tinnitus, irregular heartbeat, and leaky heart valves. Treatment includes enzyme replacement therapy (ERT).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fabry Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fabry Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fabry Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3, 2 and 4 respectively.

Fabry Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fabry Disease (Genetic Disorders).

  • The pipeline guide reviews pipeline therapeutics for Fabry Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Fabry Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Fabry Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Fabry Disease (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Fabry Disease (Genetic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Fabry Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Fabry Disease - Pipeline Review, H2 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fabry Disease - Overview
Fabry Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Fabry Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fabry Disease - Companies Involved in Therapeutics Development
Amicus Therapeutics Inc
Genzyme Corp
greenovation Biotech GmbH
Idorsia Ltd
JCR Pharmaceuticals Co Ltd
Neuraltus Pharmaceuticals Inc
Pharming Group NV
Protalix BioTherapeutics Inc
Resverlogix Corp
Sangamo Therapeutics Inc
Shire Plc
Fabry Disease - Drug Profiles
agalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
agalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apabetalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVRRD-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Alpha Galactosidase A for Fabry Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibiglustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lucerastat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
migalastat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOSS-AGAL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegunigalsidase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBLSD-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fabry Disease - Dormant Projects
Fabry Disease - Discontinued Products
Fabry Disease - Product Development Milestones
Featured News & Press Releases
Jul 11, 2017: U.S. FDA Confirms Amicus Therapeutics May Submit New Drug Application for Migalastat for Fabry Disease
Jun 28, 2017: Amicus Therapeutics Submits Japanese New Drug Application for Migalastat for Fabry Disease
Jun 01, 2017: Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility
May 30, 2017: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
May 09, 2017: Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease
May 02, 2017: Amicus Therapeutics Launches Galafold for Treatment of Fabry Disease in France
Apr 18, 2017: Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies
Mar 08, 2017: Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Italy
Feb 27, 2017: Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in the United Kingdom
Feb 16, 2017: Gene therapy used to treat Fabry disease - a world first
Feb 14, 2017: Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium 2017
Jan 04, 2017: National Institute for Health and Care Excellence Issues Final Positive Recommendation for Galafold (migalastat) for Fabry Disease in England
Nov 28, 2016: Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease
Nov 11, 2016: Journal of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study of Migalastat for Patients with Fabry Disease
Oct 25, 2016: Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Fabry Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Fabry Disease - Pipeline by Amicus Therapeutics Inc, H2 2017
Fabry Disease - Pipeline by Genzyme Corp, H2 2017
Fabry Disease - Pipeline by greenovation Biotech GmbH, H2 2017
Fabry Disease - Pipeline by Idorsia Ltd, H2 2017
Fabry Disease - Pipeline by JCR Pharmaceuticals Co Ltd, H2 2017
Fabry Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2017
Fabry Disease - Pipeline by Pharming Group NV, H2 2017
Fabry Disease - Pipeline by Protalix BioTherapeutics Inc, H2 2017
Fabry Disease - Pipeline by Resverlogix Corp, H2 2017
Fabry Disease - Pipeline by Sangamo Therapeutics Inc, H2 2017
Fabry Disease - Pipeline by Shire Plc, H2 2017
Fabry Disease - Dormant Projects, H2 2017
Fabry Disease - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Fabry Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 72
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis I - Pipeline Review, H2 2017, provides an overview of the Mucopolysaccharidosis I (Metabolic Disorders) pipeline landscape. MPS I (Mucopolysaccharidosis I) is an inherited lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). Symptoms ......
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 53
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II - Pipeline Review, H2 2017, provides an overview of the Mucopolysaccharidosis II (Metabolic Disorders) pipeline landscape. Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial fe......
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 58
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis III - Pipeline Review, H2 2017, provides an overview of the Mucopolysaccharidosis III (Metabolic Disorders) pipeline landscape. Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is an inherited metabolic disease caused by an absence or malfunctioning of certain enzymes needed to breakdown molecules called glycosaminoglycans (GAG). Symptoms include se......
  • Hyperinsulinemia - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H2 2017, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape. Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hun......
  • Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 1500 Onwards        Pages: 40
    DelveInsight's, Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Fabry Disease. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Fabry Disease which can turn out to b......
  • Fabry Disease - Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Fabry Disease -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Fabry Disease in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Insulin Resistance. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Insulin Resistance. The report contains the targeted patient population......
  • Fabry Disease - Pipeline Insight, 2017
    Published: 01-Nov-2017        Price: US 1500 Onwards        Pages: 70
    DelveInsight's, " Fabry Disease -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Fabry Disease. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Fabry Disease. This report provides information on the therapeutic development for Fabry Disease, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as d......
  • Fabry Disease - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Fabry Disease - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Fabry Disease for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Fabry Disease . It enables understanding of the historic......
  • Global Lysosomal Storage Disease Partnering 2010-2017
    Published: 01-Nov-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report pr......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs